KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Short-Term Debt issuances (2016 - 2025)

Abbott Laboratories' Short-Term Debt issuances history spans 17 years, with the latest figure at -$71.0 million for Q4 2025.

  • For Q4 2025, Short-Term Debt issuances fell 373.08% year-over-year to -$71.0 million; the TTM value through Dec 2025 reached -$115.0 million, down 15.0%, while the annual FY2025 figure was -$115.0 million, 15.0% down from the prior year.
  • Short-Term Debt issuances for Q4 2025 was -$71.0 million at Abbott Laboratories, down from $8.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $111.0 million in Q4 2023 and bottomed at -$197.0 million in Q4 2021.
  • The 5-year median for Short-Term Debt issuances is $500000.0 (2021), against an average of -$17.6 million.
  • The largest annual shift saw Short-Term Debt issuances plummeted 19600.0% in 2021 before it surged 1010.0% in 2023.
  • A 5-year view of Short-Term Debt issuances shows it stood at -$197.0 million in 2021, then soared by 105.08% to $10.0 million in 2022, then soared by 1010.0% to $111.0 million in 2023, then crashed by 76.58% to $26.0 million in 2024, then plummeted by 373.08% to -$71.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Short-Term Debt issuances are -$71.0 million (Q4 2025), $8.0 million (Q3 2025), and -$16.0 million (Q2 2025).